Press Releases

pSivida Corp. September Qtr 2008 Earnings Report WATERTOWN, MA – October 31, 2008 -- pSivida Corp. (NASDAQ: PSDV, ASX: PVA, FF: PV3), a drug delivery company, today announced that its financial results for the first quarter ended September 30, 2008 will be filed with the SEC and the ASX on or

Results from the six-month interim readout of the Human PK Iluvien Study Boston, MA – Drug delivery company, pSivida Corp. (NASDAQ: PSDV, ASX: PVA, FF: PV3), together with its licensing and development partner, Alimera Sciences have today reported the interim six-month safety and efficacy results

DSMB Supports continuation of the Phase III clinical trial of Iluvien for the treatment of DME Boston, MA (September 26, 2008) – Global drug delivery company, pSivida Corp. (NASDAQ: PSDV, ASX: PVA, FF: PV3) today announced that after completing its review of safety and efficacy data currently

pSivida Quarterly Cash Flow – June 30, 2008 Commentary and Highlights pSivida Quarterly Highlights - Reincorporation in the US Completed - Interim results from Medidur for DME Study - Commencement of new Medidur AMD Trial - Commencement of BrachySil Pancreatic Cancer Dose Ranging Clinical Trial

pSivida New Board Appointments Boston, MA (July 14, 2008) – pSivida Corp. (NASDAQ: PSDV, ASX: PVA, FF: PSI), a leading drug delivery company headquartered in Watertown, MA, is pleased to announce the appointment to their Board of Directors of Peter G. Savas and Paul A.

pSivida Corp: BrachySil™ Phase IIb Pancreatic Cancer Trials Commence Boston, MA. and Perth, Australia (July 7, 2008) – pSivida Corp. (NASDAQ: PSDV, ASX: PVA, FF: PSI), a global drug delivery company is pleased to announce that a Phase IIb clinical trial has commenced with BrachySil™ (P32

pSivida MD to ring NASDAQ Closing Bell Boston, MA and Perth, Australia (June 30, 2008) – Global drug delivery company, pSivida Corp. (NASDAQ: PSDV, ASX: PVA, FSE: PSI) today announced that Dr. Paul Ashton, Managing Director, will ring the NASDAQ Stock Market Closing Bell on Tuesday, July 1, at 4

pSivida Interim results from the 3-month Human PK Medidur FA Study Boston, MA and Perth, Australia (June 27, 2008) – Global drug delivery company, pSivida Corp. (NASDAQ: PSDV, ASX: PVA, FSE: PSI) today reported the interim three-month safety and efficacy results from the first human

Open Briefing Interview with Managing Director, Dr Paul Ashton - pSivida reincorporation in the US Date of lodgement: 20-Jun-2008 Title: Open Briefing®. pSivida. Reincorporation of pSivida to US Record of interview: corporatefile.com.au pSivida Ltd. (NASDAQ:PSDVV, ASX:PVA, FSE:PSI) has implemented

pSivida Scheme of Arrangement Implemented Boston, MA and Perth, Australia (19 June 2008) - pSivida Corp. (ASX: PVA, NASDAQ: PSDVV, FSE: PSI) announces that the Scheme of Arrangement between pSivida Limited and its shareholders has today been implemented.

Compliance with ASX Listing Rule 3.1 Boston, MA and Perth, Australia (11 June 2008) - pSivida Limited. (ASX: PSD, NASDAQ: PSDV, FSE: PSI) confirms that it is in compliance with its obligations under ASX Listing Rule 3.1 as at the date of this announcement.

NASDAQ Trading To Commence Boston, MA and Perth, Australia (June 11, 2008) – Following approval by the Federal Court of Australia of the reincorporation of pSivida Limited, a Western Australian corporation, to pSivida Corp., a new Delaware, United States corporation, pSivida Corp.